Literature DB >> 12034344

Physical consequences of schizophrenia and its treatment: the metabolic syndrome.

Martina C M Ryan1, Jogin H Thakore.   

Abstract

Schizophrenia is a life shortening illness. Unnatural causes and natural causes are put forward as reasons for this excess mortality. In terms of the latter, a host of different physical disorders occur with increased frequency in schizophrenia. When taken together, some of these illnesses such as type 2 diabetes mellitus and cardiovascular disorders constitute the Metabolic Syndrome; a characteristic phenotype of those with this syndrome is excessive visceral fat distribution. The exact reasons why this particular syndrome occurs in schizophrenia is as yet unclear though factors such as life style, poor diet and lack of exercise may contribute to it's development. Alternatively, overactivity of the hypothalamic-pituitary-adrenal axis leading to hypercortisolaemia can also result in excessive visceral fat accumulation. This minireview aims to explore the potential role of these issues and medication in terms of the increased morbidity and mortality observed in schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12034344     DOI: 10.1016/s0024-3205(02)01646-6

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  40 in total

Review 1.  Pharmacogenetics of antipsychotic-induced weight gain.

Authors:  Christoph U Correll; Anil K Malhotra
Journal:  Psychopharmacology (Berl)       Date:  2004-07-08       Impact factor: 4.530

2.  Physical Health and Dual Diagnosis.

Authors:  Debbie Robson; Sarah Keen; Pia Mauro
Journal:  Adv Dual Diagn       Date:  2008

Review 3.  Toward a model of memory enhancement in schizophrenia: glucose administration and hippocampal function.

Authors:  William S Stone; Larry J Seidman
Journal:  Schizophr Bull       Date:  2007-05-15       Impact factor: 9.306

4.  Prevalence and associations of the metabolic syndrome among patients prescribed clozapine.

Authors:  M Ahmed; I Hussain; S M O'Brien; B Dineen; D Griffin; C McDonald
Journal:  Ir J Med Sci       Date:  2008-05-07       Impact factor: 1.568

5.  Cardiovascular risk assessment and management in mental health clients: whose role is it anyway?

Authors:  Amanda J Wheeler; Jeff Harrison; Priya Mohini; Jeshika Nardan; Amy Tsai; Eve Tsai
Journal:  Community Ment Health J       Date:  2009-08-18

6.  Weight gain in newly diagnosed first-episode psychosis patients and healthy comparisons: one-year analysis.

Authors:  Martin Strassnig; Jean Miewald; Matcheri Keshavan; Rohan Ganguli
Journal:  Schizophr Res       Date:  2007-05-02       Impact factor: 4.939

7.  Metabolic syndrome in people with schizophrenia: a review.

Authors:  Marc DE Hert; Vincent Schreurs; Davy Vancampfort; Ruud VAN Winkel
Journal:  World Psychiatry       Date:  2009-02       Impact factor: 49.548

Review 8.  Lipid effects of psychiatric medications.

Authors:  Junzo Watanabe; Yutaro Suzuki; Toshiyuki Someya
Journal:  Curr Atheroscler Rep       Date:  2013-01       Impact factor: 5.113

9.  A randomised controlled study of risperidone and olanzapine for schizophrenic patients with neuroleptic-induced acute dystonia or parkinsonism.

Authors:  H Y Chan; C J Chang; S C Chiang; J J Chen; C H Chen; H J Sun; H G Hwu; M S Lai
Journal:  J Psychopharmacol       Date:  2008-09-18       Impact factor: 4.153

10.  An economic evaluation of aripiprazole vs olanzapine adapted to the Italian setting using outcomes of metabolic syndrome and risk for diabetes in patients with schizophrenia.

Authors:  Giorgio L Colombo; Mauro Caruggi; Sergio Di Matteo; Alessandro Rossi
Journal:  Neuropsychiatr Dis Treat       Date:  2008-10       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.